Provided is a composition which can be utilized for drug delivery systems that can penetrate the blood brain barrier, and has low cytotoxicity. A nanoparticle composition comprises nanoparticles to the surface of which a first substance and a second substance each having specificity to a tumor cell are bound, wherein the first substance having specificity to the tumor cell is a peptide comprising an amino acid sequence of arginine-glycine-aspartic acid, and wherein the second substance having specificity to the tumor cell is an iron-binding protein, and wherein the nanoparticles each comprise an outer layer and vesicles enveloped by the outer layer and the nanoparticles each comprise, as membrane components, a PEGylated phospholipid, a fatty acid with a melting point of 30 C. or more, and a non-PEGylated phospholipid.

Living cells, such as red blood cells (RBCs) modified with functional micromotors with the aid of ultrasound propulsion and magnetic guidance. Iron oxide nanoparticles are loaded into the RBCs, where their asymmetric distribution within the cells results in a net magnetization, thus enabling magnetic alignment and guidance under acoustic propulsion. The RBC motors display efficient guided and prolonged propulsion in various biological fluids, including undiluted whole blood.

A magnetic, thermosensitive, fluorescent micelle includes a core, a carrier wrapping the core, and a plurality of water-soluble near-infrared CdHgTe quantum dots (QD) disposed on the carrier. The core includes dextran-magnetic layered double hydroxide-fluorouracil (DMF). The carrier includes a tripolymer of poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-polylactic acid (PLA). N-isopropylacrylamide-co-N,N-dimethylacrylamide of the tripolymer includes a hydrophilic group and a hydrophobic carbon frame. The hydrophilic group is oriented outwards with respect to the and forms a shell. The hydrophobic carbon frame and polylactic acid are restrained to wrap the dextran-magnetic layered double hydroxide-fluorouracil to form the core.

The present invention relates to a resorbable implant material made of magnesium or magnesium alloy and to a process for the production thereof. A disadvantage of the known resorbable implants is that their resorption has hitherto only been trackable using x-ray or CT examinations. The invention provides a resorbable implant material comprising homogeneously distributed fluorescent nanodiamonds in a matrix of magnesium or a magnesium alloy. Fluorescent nanodiamonds are biologically nonhazardous and provide a stable emission in the near infrared range due to nitrogen-vacancy centers (NV centres). This allows detection of the implant material in the blood plasma of the patient.

The resorbable implant material according to the invention is produced by a process wherein magnesium or a magnesium alloy is melted, nanodiamonds are added to the melt and the melt of magnesium or a magnesium alloy provided with nanodiamonds is subjected to an ultrasound treatment.

A micro robot that is moveable in a body includes first quantum dots.

The present invention relates generally to nanowires, nanospheres and microspherical structures derived from keratin, such as bird feathers. Such structures may be utilized to form biodegradable, organic, non-toxic solar cells for the purpose of propogating energy in a circuit of an electronic device. Structures of the present invention can also be utilized in pharmaceutical delivery devices and biosensing purposes, in particular, detecting cancerous cells in vivo.

The present invention relates to a protein which binds to the domain encoded by exon 9 of human CD44 (CD44ex9), to fusion proteins and conjugates of said protein and especially to nanoparticles conjugated to said protein. The invention further relates to a method of production for the protein and the respective conjugated nanoparticles and the use of the protein of the invention for treatment and diagnosis of cancer diseases.

Nanoparticles include a core, a hydrophilic layer around the core, and one or more mitochondrial targeting moieties, and may optionally include one or more contrast agents or one or more therapeutic agents. For effective mitochondrial targeting the nanoparticles have a diameter of about 200 nm or less or have a zeta potential of about 0 mV or more.

An aqueous approach to synthesize capped SnS quantum dots (QDs) followed by optional capping molecule extension by attaching one or more extending molecules to the capping molecule via peptide bond formation at elevated temperature. The capped SnS QDs may have a capping molecule:Sn:S molar ratio of 16:3:1 to 16:12:1. A suspension of SnS QDs was heat-treated at 200 C. for 0.5-4 hrs. The obtained SnS QDs showed an NIR emission peak at 820-835 nm with an excitation wavelength at 690 nm. The as synthesized SnS QDs were found to have high positive zeta potential of 30 mV and thus were toxic to cells. By neutralizing the SnS QDs the cytotoxicity was reduced to an accepted level. The heat-treatment step can be obviated by adding a glycerol solution containing S.sup.2 anions and capping molecule to a glycerol solution of Sn.sup.2+ ions.

The present invention relates to a resorbable implant material made of magnesium or magnesium alloy and to a process for the production thereof. A disadvantage of the known resorbable implants is that their resorption has hitherto only been trackable using x-ray or CT examinations. The invention provides a resorbable implant material comprising homogeneously distributed fluorescent nanodiamonds in a matrix of magnesium or a magnesium alloy. Fluorescent nanodiamonds are biologically nonhazardous and provide a stable emission in the near infrared range due to nitrogen-vacancy centers (NV centres). This allows detection of the implant material in the blood plasma of the patient. The resorbable implant material according to the invention is produced by a process wherein magnesium or a magnesium alloy is melted, nanodiamonds are added to the melt and the melt of magnesium or a magnesium alloy provided with nanodiamonds is subjected to an ultrasound treatment.